A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

NCT06630871 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

NMIBC

Interventions

DRUG: Distitamab Vedotin in combination with Tislelizumab

Sponsor

Fujian Medical University Union Hospital

Collaborators

[object Object]
[object Object]